Drug Profile
Suptavumab
Alternative Names: REGN-2222; SAR-438584Latest Information Update: 17 Aug 2017
Price :
$50
*
At a glance
- Originator Regeneron Pharmaceuticals
- Class Monoclonal antibodies
- Mechanism of Action Viral fusion protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Respiratory syncytial virus infections
Most Recent Events
- 14 Aug 2017 Discontinued - Phase-III for Respiratory syncytial virus infections (In infants, In neonates, Prevention) in Australia, New Zealand, USA, Bulgaria, Denmark, Finland, Hungary, Netherlands, Puerto Rico, Spain, Sweden, United Kingdom, South Africa, Turkey, Canada, Chile, Ukraine, Panama, Germany (IM)
- 05 May 2017 Regeneron Pharmaceuticals completes enrolment in a phase III trial for Respiratory syncytial virus infections in USA Bulgaria, Denmark, Finland, Hungary, Netherlands, Puerto Rico, Spain, Sweden, United Kingdom, Australia, New Zealand, South Africa, Turkey, Canada, Chile, Ukraine, Panama, and Germany
- 01 Sep 2016 Regeneron Pharmaceuticals completes a phase I trial in Healthy volunteers in USA (IM) (NCT02828397)